Androgen sensitivity gateway to COVID-19 disease severity.


Journal

Drug development research
ISSN: 1098-2299
Titre abrégé: Drug Dev Res
Pays: United States
ID NLM: 8204468

Informations de publication

Date de publication:
11 2020
Historique:
received: 27 04 2020
revised: 04 05 2020
accepted: 06 05 2020
pubmed: 16 5 2020
medline: 15 12 2020
entrez: 16 5 2020
Statut: ppublish

Résumé

In this communication, we present arguments for androgen sensitivity as a likely determinant of COVID-19 disease severity. The androgen sensitivity model explains why males are more likely to develop severe symptoms while children are ostensibly resistant to infection. Further, the model explains the difference in COVID-19 mortality rates among different ethnicities. Androgen sensitivity is determined by genetic variants of the androgen receptor. The androgen receptor regulates transcription of the transmembrane protease, serine 2 (TMPRSS2), which is required for SARS-CoV-2 infectivity. TMPRSS2 primes the Spike protein of the virus, which has two consequences: diminishing viral recognition by neutralizing antibodies and activating SARS-CoV-2 for virus-cell fusion. Genetic variants that have been associated with androgenetic alopecia, prostate cancer, benign prostatic hyperplasia and polycystic ovary syndrome could be associated with host susceptibility. In addition to theoretical epidemiological and molecular mechanisms, there are reports of high rates of androgenetic alopecia of from hospitalized COVID-19 patients due to severe symptoms. Androgen sensitivity is a likely determinant of COVID-19 disease severity. We believe that the evidence presented in this communication warrants the initiation of trials using anti-androgen agents.

Identifiants

pubmed: 32412125
doi: 10.1002/ddr.21688
pmc: PMC7273095
doi:

Substances chimiques

AR protein, human 0
Receptors, Androgen 0
Spike Glycoprotein, Coronavirus 0
spike glycoprotein, SARS-CoV 0
Serine Endopeptidases EC 3.4.21.-
TMPRSS2 protein, human EC 3.4.21.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

771-776

Informations de copyright

© 2020 Wiley Periodicals, Inc.

Références

N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Nat Rev Genet. 2008 Dec;9(12):911-22
pubmed: 19002143
Nat Med. 2020 Feb;26(2):252-258
pubmed: 32042192
Cancer Res. 2001 Feb 15;61(4):1686-92
pubmed: 11245484
Cancer Discov. 2020 Jun;10(6):779-782
pubmed: 32276929
Eur Respir J. 2020 Jun 4;55(6):
pubmed: 32350106
Endocr Rev. 2000 Jun;21(3):245-91
pubmed: 10857554
J Cosmet Dermatol. 2020 Jul;19(7):1542-1543
pubmed: 32333494
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Crit Care. 2020 Mar 18;24(1):108
pubmed: 32188484
Genomics. 1997 Sep 15;44(3):309-20
pubmed: 9325052
J Virol. 2014 Jan;88(2):1293-307
pubmed: 24227843
Cancer Res. 1999 Sep 1;59(17):4180-4
pubmed: 10485450
Exp Clin Endocrinol Diabetes. 2012 Feb;120(2):73-9
pubmed: 22068615
PLoS One. 2015 May 26;10(5):e0127515
pubmed: 26010093
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
J Cosmet Dermatol. 2020 Jul;19(7):1545-1547
pubmed: 32301221
J Immunol. 2017 May 15;198(10):4046-4053
pubmed: 28373583
Pediatr Pulmonol. 2020 Jun;55(6):E4-E5
pubmed: 32250049
Cancer Discov. 2014 Nov;4(11):1310-25
pubmed: 25122198
J Clin Oncol. 2002 Sep 1;20(17):3599-604
pubmed: 12202660
N Engl J Med. 2020 Apr 23;382(17):1663-1665
pubmed: 32187458
Nicotine Tob Res. 2020 Aug 24;22(9):1666
pubmed: 32353120
N Engl J Med. 2020 Apr 30;382(18):1677-1679
pubmed: 32109012
J Virol. 2011 May;85(9):4122-34
pubmed: 21325420
J Am Acad Dermatol. 2020 Jul;83(1):308-309
pubmed: 32283245
Lancet Infect Dis. 2020 Jun;20(6):689-696
pubmed: 32220650
Fertil Steril. 2016 Jul;106(1):6-15
pubmed: 27233760
J Clin Endocrinol Metab. 2006 Nov;91(11):4205-14
pubmed: 16912124
Gastroenterology. 2020 May;158(6):1518-1519
pubmed: 32142785
Eur J Biochem. 2001 May;268(9):2687-99
pubmed: 11322890
Int J Infect Dis. 2020 Apr;93:205-207
pubmed: 32142979
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Int J Oral Sci. 2020 Feb 24;12(1):8
pubmed: 32094336
Dermatol Ther. 2020 Jul;33(4):e13365
pubmed: 32237190
Asian Pac J Cancer Prev. ;18(1):17-21
pubmed: 28240001
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346
pubmed: 32214079

Auteurs

Carlos Gustavo Wambier (CG)

Department of Dermatology, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.

Andy Goren (A)

Applied Biology, Inc., Irvine, California, USA.

Sergio Vaño-Galván (S)

Trichology Unit, Hospital Universitario Ramón y Cajal, Madrid, Spain.

Paulo Müller Ramos (PM)

Department of Dermatology and Radiotherapy, São Paulo State University - UNESP, São Paulo, Brazil.

Angelina Ossimetha (A)

Brown University, Providence, Rhode Island, USA.

Gerard Nau (G)

Division of Infectious Diseases, Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.

Sabina Herrera (S)

Trichology Unit, Hospital Universitario Ramón y Cajal, Madrid, Spain.

John McCoy (J)

Applied Biology, Inc., Irvine, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH